Skip to main content

Rolfe Lindsey's Form 4 filing

Clovis Oncology, Inc. (CLVS) · filed Nov 3, 2021

Accession no.
0000899243-21-042707
Filed
Nov 3, 2021
Trade date
Nov 1-2, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $19.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rolfe LindseyCIK 0001650504Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 1, 2021Common StockMOption exerciseAcquired+3,749–F1–81,871Direct
Nov 2, 2021Common StockSSaleDisposed−1,884$4.55−$8,572.279,987Direct
Nov 1, 2021Common StockMOption exerciseAcquired+4,625–F1–84,612Direct
Nov 2, 2021Common StockSSaleDisposed−2,325$4.55−$10,578.7582,287Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 1, 2021Common StockMOption exerciseDisposed−3,749$0.00$018,747Direct
Nov 1, 2021Common StockMOption exerciseDisposed−4,625$0.00$041,625Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit represents the right to receive one share of Common Stock.

Referenced by the price of 2 transactions in Table I.

Remarks

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance

Read the full filing on SEC EDGAR (opens in a new tab)